Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2008

01-01-2008 | Letter to the Editor

Lymphadenectomy in Surgical Oncology

Authors: Dimosthenis Ziogas, MD, Georgios Baltogiannis, MD, Michael Fatouros, MD

Published in: Annals of Surgical Oncology | Issue 1/2008

Login to get access

Excerpt

Randomized controlled trials (RCTs) are the gold standard for decision-making on the choice of the best treatment for patients with solid cancer. Gervasoni et al.1 in a comprehensive review that included most but not all data from RCTs and observational studies report that lymphadenectomy does not improve survival. …
Literature
1.
Gervasoni J Jr, Sbayi S, Cady B. Educational review role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol DOI: 10.1245/s10434-007-9360-5
2.
Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med 2007; 356(23):2399–405PubMedCrossRef
3.
Wu CW, Hsiung SA, Lo, et al. Nodal dissection for patients with gastric cancer: a randomised trial. Lancet Oncol 2006; 7:309–15
4.
Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7(4):253–5PubMedCrossRef
5.
Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgascouchell S. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 1990; 116(3):307–13CrossRef
6.
Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228(4):449–61PubMedCrossRef
7.
Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80(1):16–24PubMed
8.
Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81(2):59–62PubMedCrossRef
9.
Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22:2069–77PubMedCrossRef
10.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107PubMedCrossRef
11.
Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11(8):727–30PubMedCrossRef
12.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30PubMedCrossRef
13.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9(3):220–1PubMedCrossRef
14.
15.
Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11(2):127–9PubMedCrossRef
Metadata
Title
Lymphadenectomy in Surgical Oncology
Authors
Dimosthenis Ziogas, MD
Georgios Baltogiannis, MD
Michael Fatouros, MD
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9617-z

Other articles of this Issue 1/2008

Annals of Surgical Oncology 1/2008 Go to the issue

Healthcare Policy and Outcomes

Survival and Health Outcomes After Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Appendiceal Origin

Endocrine Tumors

Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer

Breast Oncology

Comments to the Letter to the Editor by Dr. Ponzone

Gastrointestinal Oncology

Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy?

Breast Oncology

Development of New Cancers in Patients with DCIS: The M.D. Anderson Experience

Letter

The Negative Sestamibi Scan: Is a Minimally Invasive Parathyroidectomy Still Possible?